Supplementary Materials: Predicting the efficacy of variant-modified COVID-19 vaccine boosters

Supplementary Tables

Refer- ence	Previous immunological history of study participants	Dosage	Vaccines reported	Variants tested	Neutralisa tion measured after [^]	Data derived from
1	BNT162b2 primary vaccination 3-7 months prior, no prior infections	nr	BNT162b2 (Ancestral) MVD614 (Ancestral) MVB.1.351 (Beta)	Ancestral, Beta, Delta, BA.1	15 d	Figure 1
2	primary vaccination and booster (~95% received mRNA vaccines for both, remainder received Ad26.COV2.S for one or both of primary / booster doses). Booster given 112-333 days prior Grouped by either (A) no prior infections or (B) infection >=110 days prior	50µg	mRNA-1273 (Ancestral) mRNA-1273.529 [#] (BA.1) combination of mRNA-1273.351 and mRNA-1273.529 [#] (Beta+BA.1) combination of mRNA-1273.617.2 [#] and mRNA-1273.529 [#] (Delta+BA.1), combination of mRNA-1273 and mRNA-1273.529 [#] (Ancestral+BA.1)	Ancestral, Beta, Delta, BA.1	15 d	Table S4
3	mRNA-1273 primary vaccination >6 months prior, no prior infections	50μg 100μg (mRNA- 1273.211 only)	mRNA-1273 (Ancestral) mRNA-1273.211 (Ancestral + Beta)	Ancestral, Beta, Delta, BA.1*	28 d	Table S4
4	mRNA-1273 primary vaccination and mRNA-1273 booster >3 months prior. Grouped by either (A) no prior infection and (B) infection >3 months prior	50µg	mRNA-1273 (Ancestral) mRNA-1273.214 (Ancestral + BA.1)	Ancestral, BA.1, BA.4/5*	28 d	Tables S7 and S8
5	primary vaccination and booster [§] , no prior infection	50µg	mRNA-1273 (Ancestral) mRNA-1273.214 (Ancestral + BA.1)	BA.4/5	1 mo	Text

6	BNT162b2 primary vaccination and BNT162b2 booster >4.7 months prior, no prior infections	30µg 60µg	BNT162b2 (Ancestral), BNT162b2 Omi (BA.1), BNT162b2 + BNT162b2 Omi (Ancestral + BA.1)	Ancestral, BA.1, BA.4/5*	1 mo	Slides labelled CC8-CC19
7	mRNA-1273 primary vaccination >5 months prior, no prior infection	50μg 20μg (mRNA- 1273.351 only)	mRNA-1273 (Ancestral) mRNA-1273.351 (Beta) mRNA-1273.211 (Ancestral + Beta)	Ancestral, Beta, Gamma, Delta*	15 d or 29 d	Figures 3, 4 and S1
8	mRNA-1273 primary vaccination, no prior infections	100ug 50ug for mRNA- 1273.211)	mRNA-1273 (Ancestral) mRNA-1273.211 (Ancestral + Beta), mRNA-1273.213 (Beta + Delta)	Ancestral, Beta, Delta, and BA.1*	29 d	Figure S6

Supplementary Table 1 Reports of Variant modified vaccines used in this analysis

nr = not reported, BA.1 and BA.4/5 refer to Omicron BA.1 and Omicron BA.4/5 variants respectively, [#] technical names not listed in reference, but inferred from clinical trial number NCT05289037, * Results were not reported for all booster-variant combinations, [^] d=days, mo=months, [§]details of primary and booster vaccine not listed

Identifying Studies to use in this analysis

We surveyed the academic literature (published works and pre-prints), manufacturer pressreleases and information provided to regulators for data on variant-modified vaccine immunogenicity. Where we identified multiple reports of the same underlying cohort or trial (e.g. a pre-print and press-release presenting the same information from a specific trial), we collected information from the report containing the most complete information only. We identified 8 reports with unique information on variant-modified vaccine immunogenicity up to 15 July 2022.

The studies identified for this analysis are shown in **Supplementary Table 1**.

Extracting data from relevant studies

For each study identified in **Supplementary Table 1**, we extracted information on the booster composition(s), the dose(s) administered, and the variants against which neutralising antibodies were tested in vitro. For each vaccine immunogen / dose / in vitro variant combination we recorded the geometric mean neutralising antibody titre (GMT) pre- and post-vaccination (for all reported assays). Where available, neutralising antibody titres at two weeks following the booster dose were used. However if these were not available, titres from up to one month following boost were used.

In the one case where exact neutralising antibody levels were not reported⁶ the ratio between neutralising antibody levels against a variant of concern and against the ancestral virus was extracted instead.

For all further analysis, extracted data was grouped by study, vaccine composition, assay and booster dose to ensure comparisons were only made between matched ancestral-based and variant-modified vaccines.

Fold-rise in antibodies after boosting

To calculate the fold rise in neutralising antibody levels after boosting (with either a variantmodified vaccine or an ancestral-based vaccine) we divided the reported GMT post-boost neutralising antibody levels for each variant tested in vitro with the matched GMT pre-boost neutralising antibody levels for the same in vitro variant (matching data by study, dose and assay). That is, the formula governing the fold-change (*FC*) calculation is

$$FC(v,m,d,s,a) = \frac{NAb_{post}(v,m,d,s,a)}{NAb_{pre}(v,m,d,s,a)}$$

Equation 1

Where, NAb_{post} is the GMT of the neutralising antibody titres following booster dose, NAb_{pre} is the GMT of the neutralising antibody titres prior to the booster dose, v is the variant tested, m is the makeup of the booster vaccine, d is the dose administered, s is the study and ais the assay used.

Fold-rise in neutralising antibody titres for a specific booster vaccine

For a specific booster vaccine makeup m we can determine the geometric mean fold rise in neutralising antibody titres, $\overline{FC(m)}$, by taking the geometric mean of Equation 1 over all available variants tested, doses administered, studies considered and assays used. Thus, the geometric mean fold rise in neutralising antibody titres for a specific booster vaccine is given by

$$\overline{FC(m)} = \left(\prod_{all \ v,d,s,a} FC(v,m,d,s,a)\right)^{\frac{1}{N_m}}$$

Equation 2

Where N_m is the number of unique combinations available in our extracted data of v, d, s and a for vaccine makeup m.

Improvement for a variant-modified vaccine boost compared to an ancestral-based vaccine boost

To estimate the improvement gained by boosting with a variant-modified vaccine over boosting with an ancestral-based vaccine, we compared the neutralising antibody titres following boosting with a particular variant-modified vaccine to the corresponding neutralising antibody titres after boosting with an ancestral-based vaccine (matching data based on study, variant tested in vitro, assay and dose administered). The formula governing the improvement (*I*) is given by:

$$I(v,m,d,s,a) = \frac{NAb_{post}(v,m,d,s,a)}{NAb_{post}(v,m_A,d,s,a)}$$

Equation 3

Where v, m, d, s and a are as defined above, and m_A refers to the ancestral-based vaccine.

We can then calculate the geometric mean improvement for a group *K* of variant-based boosters, $\overline{I(K)}$, using the formula

$$\overline{I(K)} = \left(\prod_{m \in K} \left(\prod_{all \ \nu, d, s, a} I(\nu, m, d, s, a)\right)^{\frac{1}{N_m}}\right)^{\frac{1}{N_K}}$$

Equation 4

Where N_K is the size of the group K.

Matching of vaccine immunogen and variant tested

We determined that the variant tested (*v*) was matched to vaccine immunogen (or vaccine make-up, *m*) if the variant tested was one of *any* of the variants that went into the vaccine makeup. Therefore, when testing neutralisation of the Omicron BA.1 variant in vitro, this would have been considered to be matched with any of the following vaccines; (i) a monovalent BA.1 vaccine, (ii) a bi-valent vaccine containing BA.1 and ancestral virus spike or (iii) a bi-valent vaccine containing BA.1 and ancestral virus spike or (iii) a bi-valent vaccine containing BA.1 and any other variant spike (e.g. Beta or Delta). However, it would be considered non-matched to either an ancestral-based vaccine, or a variant modified vaccine that did not include the BA.1 variant spike. By a similar argument, when testing the neutralising antibody titres against the ancestral virus in vitro, the ancestral variant would be considered to be matched vaccine, as well as with any variant-modified vaccine that also included the ancestral spike in its make-up.

Waning of neutralising antibodies

Following boosting, neutralising antibodies are assumed to wane back to their pre-boost level with a half-life of 108 days ⁹⁻¹¹. Therefore, if the neutralising antibody titres prior to boosting were given by n_0 , then at t days after an f-fold boost in neutralising antibody titres due to vaccination, neutralising antibody titres, $n_{boost}(t, f, n_0)$ would be given by

$$n_{boost}(n_0, f, t) = \max\left(fn_0e^{-\frac{\ln(2)t}{108}}, n_0\right)$$

Equation 5

Calculating the average efficacy over a period of time, T, after boosting

In order to determine the average efficacy within a group of subjects over a fixed period of time following boosting (either by an ancestral-based or variant-modified booster vaccine) we first need to know the pre-boost level of neutralising antibody titres. This is equivalent to knowing the pre-boost symptomatic efficacy (labelled as VE_0) within the population from which the subjects are taken.

Given VE_0 , the fold rise (f) in neutralising antibody titres due to the vaccine boost and a period of time (T), we can follow the steps 1-4 below to calculate the average efficacy over the time period after boosting:

1) Establish the average baseline neutralising antibody titres in the population.

We can calculate the average neutralising antibody titres within the population using our established relationship between neutralising antibody levels and vaccine efficacy¹⁰. This is done by using the inverse of the relationship between neutralising antibody titres and vaccine protection previously established in *Khoury et. al*¹⁰. For neutralising antibody titres given by *n*, the original relationship takes the form

$$VE(n) = \int_{-\infty}^{\infty} N(x, \log 10(n), \sigma) \frac{1}{1 - e^{-k(x - x_{50})}} dx$$

Equation 6

Where VE(n) is the vaccine efficacy (compared to a naïve population) for a population with average neutralising antibody titres of n, N is the probability density function of a normal distribution with mean n and standard deviation σ , σ is the previously reported standard deviation (0.46) in neutralising antibody titres and k (3.1) and x_{50} (log₁₀(0.20)) are logistic parameters fitted in *Khoury* et. al.¹⁰ from randomized controlled trial data.

Given a pre-boost level of protection from symptomatic disease of VE_0 , we can numerically calculate the corresponding average neutralising antibody titres in the population, n_0 , by using the inverse of Equation 6. We will represent these population average neutralising antibody titres for a given pre-boost symptomatic efficacy, VE_0 , as $\hat{n}(VE_0)$. 2) Calculate the neutralising antibody titres at a given time, t, after boosting

For a given fold-boost in neutralising antibody titres due to a vaccine, we use n_0 determined in step 1 above and Equation 5 to calculate the neutralising antibody titres t days after boosting.

3) Establish the new efficacy (compared to a naïve population) at a given time, t, after boosting

For the neutralising antibody titres calculated in step 3 above, we use Equation 6 and Equation 5 to calculate the new efficacy t days after boosting. Therefore, efficacy at a given time, t, after an f-fold boost in a population with average neutralising antibody titres of n_0 , $VE_{boost}(n_0, f, t)$, is given by:

$$VE_{boost}(n_0, f, t) = \int_{-\infty}^{\infty} N(x, \log 10(n_{boost}(n_0, f, t)), \sigma) \frac{1}{1 - e^{-k(x - x_{50})}} dx$$
Equation 7

4) Determine the average efficacy over time-period T after boosting

We next integrate Equation 7 from the time of boosting until the end of the time-period T to determine the average efficacy over time-period T after boosting with an and f-fold boost in a population with average neutralising antibody titres of n_0 , $\overline{VE_{boost}}(n_0, f, T)$. This results in the following expression:

$$\overline{VE_{boost}}(n_0, f, T) = \frac{1}{T} \int_0^T VE_{boost}(n_0, f, t) dt$$

Equation 8

Average efficacy improvement for a variant-modified vaccine over an ancestral-based vaccine

To determine the efficacy improvement for a variant-modified vaccine over an ancestral-based vaccine we first determine the fold-change in neutralising antibody titres for the ancestral-based vaccine, $\overline{FC(m_A)}$ using Equation 2 and label this as f_A . The improvement for a group K, of variant-modified vaccines is given in Equation 4 by $\overline{I(K)}$.

Therefore, the average efficacy over time-period T after giving an ancestral-based boost in a population with a pre-boost symptomatic efficacy of VE_0 is given by $\overline{VE_{boost}}(\hat{n}(VE_0), f_A, T)$ and the average efficacy over time-period T after giving a variant-specific boost with a variant-specific vaccine from group K in a population with a pre-boost symptomatic efficacy of VE_0 is

given by $\overline{VE_{boost}}(\hat{n}(VE_0), f_A\overline{I(K)}, T)$. Combining these expressions together, we find that the improvement in protection for a variant-modified vaccine (from a group *K* of variant-modified vaccines) over an ancestral-based vaccine (denoted by IP(K)) is given by:

$$IP(K) = \overline{VE_{boost}} \left(\hat{n}(VE_0), f_A \overline{I(K)}, T \right) - \overline{VE_{boost}} (\hat{n}(VE_0), f_A, T)$$

Equation 9

We note that the units of IP(K), the improvement in protection, are in percentage points.

References

- 1 Launay, O. *et al.* Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. *N Engl J Med* **387**, 374-376 (2022). <u>https://doi.org:10.1056/NEJMc2206711</u>
- 2 Branche, A. R. *et al.* SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. *medRxiv* (2022). <u>https://doi.org:10.1101/2022.07.12.22277336</u>
- 3 Chalkias, S. *et al.* Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine. *Research Square* (2022). <u>https://doi.org:10.21203/rs.3.rs-1555201/v1</u>
- 4 Chalkias, S. *et al.* A Bivalent Omicron-containing Booster Vaccine Against Covid-19. *medRxiv*, 2022.2006.2024.22276703 (2022). https://doi.org:10.1101/2022.06.24.22276703
- 5 Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster (Moderna Press Release, 11 July, 2022). <u>https://www.accesswire.com/708109/Modernas-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273214-Demonstrates-Significantly-Higher-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA45-Compared-To-Currently-Authorized-Booster (2022).</u>
- 6 Swanson, K. A. Pfizer/BioNTech COVID-19 Omicron-Modified Vaccine Options in Vaccines and Related Biological Products Advisory Committee Meeting. 28 June, 2022 <u>https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement</u> (27 July 2022).
- 7 Choi, A. *et al.* Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med* 27, 2025-2031 (2021). <u>https://doi.org:10.1038/s41591-021-01527-y</u>
- Pajon, R. *et al.* SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. *N Engl J Med* 386, 1088-1091 (2022).
 <u>https://doi.org:10.1056/NEJMc2119912</u>
- 9 Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* **371** (2021). <u>https://doi.org:10.1126/science.abf4063</u>
- 10 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021). https://doi.org:10.1038/s41591-021-01377-8
- 11 Cromer, D. *et al.* Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet Microbe* **3**, e52-e61 (2022). <u>https://doi.org:10.1016/S2666-5247(21)00267-6</u>